Merck & Co. MRK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.24B-183% | $2.96B-20.9% | $5.79B+83.1% | $4.43B-18.9% | $5.09B+6.7% | ||
| $185M-5.1% | $205M+9.6% | $204M+4.6% | $216M+6.4% | $195M+10.8% | ||
| -$315M-69.4% | -$825M-33.9% | -$212M+47.1% | -$448M-148% | -$186M-265% | ||
| —— | $272.5M+347% | $272.5M+347% | $272.5M+347% | $272.5M+347% | ||
| —— | $295M+41.3% | $295M+41.3% | $295M+41.3% | $295M+41.3% | ||
| —— | $27.5M-39.6% | $27.5M-39.6% | $27.5M-39.6% | $27.5M-39.6% | ||
| —— | -$460.25M+20.9% | -$460.25M+20.9% | -$460.25M+20.9% | -$460.25M+20.9% | ||
| —— | $48.75M+498% | $48.75M+498% | $48.75M+498% | $48.75M+498% | ||
| —— | $34.25M-86.6% | $34.25M-86.6% | $34.25M-86.6% | $34.25M-86.6% | ||
| $3.92B+56.7% | $2.86B-17.2% | $7.82B-15.8% | $3.29B-41.6% | $2.5B-19.1% | ||
| $991M-25.4% | $1.03B+10.2% | $987M+26.1% | $764M-3.4% | $1.33B+54.2% | ||
| $8.78B— | $10.04B+847% | $0-100% | $0— | $0-100% | ||
| $374M-37.1% | —— | —— | $612M+1,149% | $595M+3,867% | ||
| -$10.21B-587% | -$11.2B-676% | -$283M+92.6% | -$770M+28.0% | -$1.49B-8.1% | ||
| $2.11B+2.7% | $2.02B+3.4% | $2.03B+4.0% | $2.08B+4.6% | $2.05B+5.1% | ||
| $874M-24.9% | $1.25B+156% | $1.32B+198% | $1.35B+436% | $1.16B+854% | ||
| $1.14B-54.4% | $2M-99.6% | $1M— | $0— | $2.5B+233% | ||
| $157M+726% | $47M+292% | $14M+180% | $12M-83.6% | $19M-78.2% | ||
| -$2.98B+48.2% | —— | —— | -$3.56B— | -$5.76B-105% | ||
| -$19M-112% | $23M+106% | $10M-96.6% | $374M+556% | $156M+213% | ||
| -$9.29B-103% | —— | $10.19B+207% | -$659M-112% | -$4.59B-270% | ||
| -$20M+81.7% | -$118M— | $0+100% | -$335M-268% | -$109M-31.3% | ||
| $931M+55.9% | $973M+44.1% | $622M-1.7% | $601M-2.1% | $597M+26.2% | ||
| $581M+15.7% | $1.49B+186% | $532M-3.8% | $518M0.0% | $502M-1.8% | ||
| $168M+86.7% | —— | $373M+1,303% | $100M+78.6% | $90M-37.1% | ||
| —— | $27.5M-39.6% | $27.5M-39.6% | $27.5M-39.6% | $27.5M-39.6% | ||
| $1.61B-56.5% | —— | —— | $2.26B+123% | $3.71B+9.8% | ||
| -$20M+81.7% | -$118M— | $0+100% | -$335M-268% | -$109M-31.3% | ||
| $8.54B— | $0-100% | $0-100% | $0— | $0-100% | ||
| $66M+230% | $172M+202% | -$129M— | $0-100% | $20M+42.9% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$80M-33.3% | —— | —— | -$194M+11.8% | -$60M+23.1% | ||
| $1.06B— | —— | $15M— | $48M— | $0— | ||
| $2.93B+150% | $1.82B-27.4% | $6.84B-19.7% | $2.53B-47.8% | $1.17B-47.4% | ||
| $2.93B+150% | $1.82B-27.4% | $6.84B-19.7% | $2.53B-47.8% | $1.17B-47.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Merck & Co. generate?
- Merck & Co. (MRK) generated $17.9B in operating cash flow over the trailing twelve months.
- What is Merck & Co.'s free cash flow?
- After $3.8B of capital expenditures, Merck & Co.'s free cash flow was $14.1B over the trailing twelve months, down 17.2% year over year.
- Where does Merck & Co.'s cash flow data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
